From: Fauci, Anthony (NIH/NIAID) [E]

Sent: Sat, 22 Feb 2020 19:41:42 +0000
To: David Willman
Subject: FW: HHS Engages Sanofi’s Recombinant Technology for 2019 Novel Coronavirus
Vaccine
David:
See press release below regarding BARDA and Sanofi.
Best,
Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone KOK

FAX: (301) 496-4409
E-mail:f
The information in this e-mail and any of its attachments is confidential and may contain sensitive
information. It should not be used by anyone who Is not the original intended recipient. If you
have received this e-mail in error please inform the sender and delete it from your mailbox or any
other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not
accept liability for any statements made that are the sender's own and not expressly made on
behalf of the NIAID by one of its representatives.

  

From: Cassetti, Cristina (NIH/NIAID) (EJ

Sent: Saturday, February 22, 2020 2:26 PM

To: Fauci, Anthony (NIH/NIAID) [E] [OY 6 >
Ce: Erbelding, Emily (NIH/NIAID) [E] [OY

Subject: Fwd: HHS Engages Sanofi’s Recombinant Tech “olosy jor 2019 Novel Coronavirus Vaccine
This is the press release from ASPR, in case you need more information on the Sanofi CoV efforts

Cristina

Begin forwarded message:

From: "Folkers, Greg (NIH/NIAID) [E}" [E>

Date: February 18, 2020 at 3:07:21 PM EST
Subject: HHS Engages Sanofi’s Recombinant Technology for 2019 Novel Coronavirus
Vaccine

NIH-001642
